- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03722433
Probiotics in the Reduction of Adverse Effects and Dysbiosis of H. Pylori Eradication
The Efficacy of Probiotic Supplementation in the Reduction of Adverse Effects and Dysbiosis of Helicobacter Pylori Eradication Therapy - A Double Blind, Multi-center Randomized, Placebo Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Backgroud: Helicobacter pylori infection has been shown to be associated with the development of gastric cancer and peptic ulcer diseases. Eradication of H. pylori infection reduces the risk of gastric cancer and the recurrence rate of peptic ulcer disease. However, the adverse effects, such as diarrhea and abdominal pain occurred in about 20-30% of patient during eradication therapies for H. pylori. Dysbiosis of the gut microbiota might contribute to the adverse effects.
Aims: Therefore, the investigators aimed to assess the efficacy of probiotic supplementation during the eradication therapy with 14-day sequential therapy in the reduction of adverse effects and the restoration of the dysbiosis.
Methods:
This will be a double-blind, placebo controlled, multi-center randomized trial. 200 patients with H. pylori infection naïve to eradication therapy will be enrolled.
Before First Line Treatment: Any two positive of CLO test, histology, serology and culture or a positive UBT will be considered as H. pylori infected.
After First Line Treatment: C13-UBT will be used to assess the existence of H. pylori 6-8 weeks after 14-day sequential therapy
Long term reinfection: C13-UBT will be used to assess the recurrence of H. pylori 1 year after14-day sequential therapy
Interventions: First line therapy: eligible patients will be randomized into one of the two groups.
Group (A): probiotic plus 14-day sequential therapy D1-D56: probiotics 1 pack bid for 56 days D1-D7: (esomeprazole + amoxicillin bid) for 7 days D8-D14: (esomeprazole + clarithromycin + metronidazole bid) for another 7 days
Group (B): placebo plus 14-day sequential therapy D1-D56: placebo 1 pack bid for 56 days D1-D7: (esomeprazole + amoxicillin bid) for 7 days D8-D14: (esomeprazole + clarithromycin + metronidazole bid) for another 7 days
Follow-up
- The stool samples will be collected before, and 2 and 8 weeks and 1 year after eradication therapy to analyze the changes in the antibiotic resistance and microbiota of gut flora
- The body weight, waist and hip circumference and serum lipid profile, sugar, and HBA1C levels will be collected before , and 2 and 8 weeks and 1 year after eradication therapy
- Determination of antibiotic resistance of H. pylori: Agar dilution test will be used to determine the minimum inhibitory concentrations of antibiotics. Mutations in 23S rRNA will also be determined by PCR followed by direct sequencing
Outcome Measurement:
Primary End Point: Incidence of adverse effects in the first line therapy in the two treatment groups
Secondary End Point:
- Eradication rates in the first line treatment in the two treatment groups
- Changes of gut microbiota in the two treatment groups
- Antibiotic resistance of gut flora after first line treatments in the two treatment groups
- Re-infection rate one year after eradication therapy
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Taipei, Taiwan, Taiwan, 10002
- Recruiting
- Jyh-Ming Liou
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult patients aged greater than 20 years with H. pylori infection naïve to treatment are considered eligible for enrollment.
Exclusion Criteria:
- children and teenagers aged less than 20 years
- history of gastrectomy
- gastric malignancy, including adenocarcinoma and lymphoma
- previous allergic reaction to antibiotics (amoxicillin, metronidazole, clarithromycin, probiotics) and PPI (esomeprazole)
- contraindication to treatment drugs
- pregnant or lactating women
- severe concurrent disease
- concomitant use of clopidogrel
- unwilling to accept random assignment of subjects
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: probiotic plus 14-day sequential therapy
D1-D56: probiotics 1 pack bid for 56 days D1-D7: (esomeprazole + amoxicillin bid) for 7 days D8-D14: (esomeprazole + clarithromycin + metronidazole bid) for another 7 days
|
Vigiis 101-LAB is the probiotic containing Lactobacillus paracasei subsp.
Paracasei, which is the isolate from Taiwanese by Prof. Pan.
This strain is resistant to gastric acid and bile acid.
Therefore, its survival rate in the gastrointestinal tract could be as high as 95%.
Previous studies showed that Vigiis 101-LAB can modulate the gut microbiota, with 10% increase in Bifidobacterium species and 20% reduction in Clostridium difficile.
|
PLACEBO_COMPARATOR: placebo plus 14-day sequential therapy
D1-D56: placebo 1 pack bid for 56 days D1-D7: (esomeprazole + amoxicillin bid) for 7 days D8-D14: (esomeprazole + clarithromycin + metronidazole bid) for another 7 days
|
Placebo without Vigiis 101-LAB component
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse effects in the first line therapy in the two treatment groups
Time Frame: 8 weeks
|
At enrollment, the patients will be informed of the common side effects from the studied drugs and they will be asked to record these symptoms during treatment.
A standardized interview and questionnaire will be used to assess the adverse events and compliance at the end of treatment.
Patients with low compliance as defined by taking less than 80% of the pills and those lost to follow up will be excluded from the per-protocol analysis.
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Eradication rates in the first line treatment in the two treatment groups
Time Frame: 6 weeks
|
Urea breath testing will be done at least 6 weeks after completion of eradication therapy.
|
6 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201706036MIPA
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Helicobacter Pylori Infection
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...RecruitingHelicobacter Pylori Infection | Helicobacter Pylori EradicationBangladesh
-
Shandong UniversityRecruitingHelicobacter Pylori Infection | Patient Education | Helicobacter Pylori EradicationChina
-
Shandong UniversityCompletedHelicobacter Pylori Infection Helicobacter Pylori Eradication Patient EducationChina
-
Shanghai Jiao Tong University School of MedicineCompletedCure Rate of Helicobacter Pylori InfectionChina
-
Seoul National University Bundang HospitalRecruitingHelicobacter Pylori Infection | Helicobacter Pylori 23S rRNA Clarithromycin Resistance Mutation | Helicobacter Pylori Associated Gastrointestinal Disease | Helicobacter Pylori Infection, Susceptibility toKorea, Republic of
-
The First Affiliated Hospital of Nanchang UniversityUnknownBacterial Infection Due to Helicobacter Pylori (H. Pylori) | Eradication Therapy of Helicobacter Pylori | Detection of Helicobacter PyloriChina
-
Tanta UniversityNot yet recruitingPersistent Helicobacter Pylori InfectionEgypt
-
Nanjing First Hospital, Nanjing Medical UniversityCompletedHelicobacter Pylori 23S rRNA/gyrA Gene Mutation Detection Kit (Fluorescence PCR Fusion Curve Method)Helicobacter Pylori Infection | Helicobacter Pylori gyrA Levofloxacin Resistance Mutation | Fecal Drug Resistance Gene Detection | Helicobacter Pylori Infection, Susceptibility toChina
-
National University Hospital, SingaporeUnknownHELICOBACTER PYLORI INFECTIONSSingapore
-
Kaohsiung Veterans General Hospital.Kaohsiung Medical University Chung-Ho Memorial HospitalCompletedHelicobacter Pylori InfectionTaiwan
Clinical Trials on Vigiis 101-LAB and sequential therapy
-
SunWay Biotech Co., LTD.National Taiwan University Hospital; Chung Shan Medical UniversityCompletedGastrointestinal MicrobiomeTaiwan
-
SunWay Biotech Co., LTD.CompletedGastrointestinal MicrobiomeTaiwan
-
SunWay Biotech Co., LTD.RecruitingOverweight | Body Weight | Body FatTaiwan
-
National Taiwan University HospitalCompleted
-
University of AlbertaCanadian Institutes of Health Research (CIHR); Alberta Innovates Health Solutions and other collaboratorsCompleted
-
Incheon St.Mary's HospitalUnknownHelicobacter Pylori InfectionKorea, Republic of
-
Beijing GoBroad HospitalNot yet recruitingAcute Lymphoblastic Leukemia, in Relapse | B-cell Acute Lymphoblastic Leukemia
-
Shandong UniversityCompletedHelicobacter Pylori Eradication RateChina
-
The University of Texas Health Science Center,...Baylor College of Medicine; University of Texas; Texas Tech University; University...CompletedIron DeficiencyUnited States
-
University of IndianapolisUnknownSpinal Nerve Root Disorder NosUnited States